1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Illumina, Inc.
  6. News
  7. Summary
    ILMN   US4523271090

ILLUMINA, INC.

(ILMN)
  Report
Real-time Estimate Cboe BZX  -  01:58 2022-08-09 pm EDT
214.73 USD   -3.70%
08/08Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics
PR
08/04Illumina Ventures Announces Expansion of its Europe Team
BU
08/03Regeneron quarterly profit slips as COVID antibody sales dry up
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Illumina Shares Drop 10% After CFO Departure

06/10/2022 | 09:04am EDT

By Kathryn Hardison


Illumina Inc. shares fell 10% Friday to $201.95, the day after the company said finance chief Sam Samad is stepping down.

Mr. Samad, who has been the company's CFO for more than 5 years, will depart July 8, Illumina said Thursday. Joydeep Goswami, chief strategy and corporate development officer, will serve as interim CFO as the company searches for a permanent replacement.

Mr. Goswami previously worked at Thermo Fisher Scientific Inc. and McKinsey & Co.

Shares of Illumina, which specializes in DNA sequencing and array-based technologies, are down 47% so far this year and down 55% over the past 12 months.


Write to Kathryn Hardison at kathryn.hardison@wsj.com


(END) Dow Jones Newswires

06-10-22 1104ET

Stocks mentioned in the article
ChangeLast1st jan.
ILLUMINA, INC. -3.93% 214.2612 Delayed Quote.-41.39%
THERMO FISHER SCIENTIFIC -0.98% 578.25 Delayed Quote.-11.54%
All news about ILLUMINA, INC.
08/08Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressi..
PR
08/04Illumina Ventures Announces Expansion of its Europe Team
BU
08/03Regeneron quarterly profit slips as COVID antibody sales dry up
RE
07/27EU Antitrust Regulators To Block Illumina, Grail Merger Despite Concessions
MT
07/27EXCLUSIVE : EU antitrust regulators likely to block Illumina, Grail deal - sources
RE
07/27Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boost..
PR
07/27Illumina Unveils Its Most Accurate and Comprehensive Secondary Analysis Platform, Boost..
CI
07/27Illumina offers patent licences to rivals, patent truce with BGI - sources
RE
07/19EU Alleges Illumina Illegally Closed Buyout of Grail and Might Face Hefty Fine -- 2nd U..
DJ
07/19Illumina Breached EU Merger Rules by 'Implementing' Grail Deal Before End of Regulatory..
MT
More news
Analyst Recommendations on ILLUMINA, INC.
More recommendations
Financials (USD)
Sales 2022 5 207 M - -
Net income 2022 449 M - -
Net cash 2022 557 M - -
P/E ratio 2022 76,2x
Yield 2022 -
Capitalization 35 030 M 35 030 M -
EV / Sales 2022 6,62x
EV / Sales 2023 5,52x
Nbr of Employees 9 825
Free-Float 79,4%
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 222,98 $
Average target price 308,25 $
Spread / Average Target 38,2%
EPS Revisions
Managers and Directors
Francis A. deSouza President, Chief Executive Officer & Director
Joydeep Goswami Chief Financial & Strategy Officer
John Wendell Thompson Chairman
Phillip G. Febbo Chief Medical Officer
Alex Aravanis CTO, Head-Research & Product Development
Sector and Competitors
1st jan.Capi. (M$)
ILLUMINA, INC.-41.39%35 030
THERMO FISHER SCIENTIFIC-11.54%228 785
DANAHER CORPORATION-12.77%208 770
INTUITIVE SURGICAL, INC.-33.45%85 396
EDWARDS LIFESCIENCES CORPORATION-18.09%65 379
SIEMENS HEALTHINEERS AG-21.45%59 158